CAI
Price
$18.30
Change
-$0.45 (-2.40%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
5.17B
45 days until earnings call
Intraday BUY SELL Signals
HRMY
Price
$37.27
Change
+$1.25 (+3.47%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
2.16B
38 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CAI vs HRMY

CAI vs HRMY Comparison Chart in %
View a ticker or compare two or three
VS
CAI vs. HRMY commentary
Jul 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CAI is a Hold and HRMY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2026
Stock price -- (CAI: $18.50 vs. HRMY: $35.47)
Brand notoriety: CAI and HRMY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CAI: 210% vs. HRMY: 203%
Market capitalization -- CAI: $5.17B vs. HRMY: $2.16B
CAI [@Biotechnology] is valued at $5.17B. HRMY’s [@Biotechnology] market capitalization is $2.16B. The market cap for tickers in the [@Biotechnology] industry ranges from $134.02B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CAI’s FA Score shows that 1 FA rating(s) are green whileHRMY’s FA Score has 0 green FA rating(s).

  • CAI’s FA Score: 1 green, 4 red.
  • HRMY’s FA Score: 0 green, 5 red.
According to our system of comparison, HRMY is a better buy in the long-term than CAI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CAI’s TA Score shows that 5 TA indicator(s) are bullish while HRMY’s TA Score has 5 bullish TA indicator(s).

  • CAI’s TA Score: 5 bullish, 3 bearish.
  • HRMY’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, HRMY is a better buy in the short-term than CAI.

Price Growth

CAI (@Biotechnology) experienced а -1.07% price change this week, while HRMY (@Biotechnology) price change was +3.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.30%. For the same industry, the average monthly price growth was +5.93%, and the average quarterly price growth was +1921.84%.

Reported Earning Dates

CAI is expected to report earnings on Aug 18, 2026.

HRMY is expected to report earnings on Aug 11, 2026.

Industries' Descriptions

@Biotechnology (+2.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CAI($5.17B) has a higher market cap than HRMY($2.16B). HRMY YTD gains are higher at: -5.211 vs. CAI (-31.431). HRMY has higher annual earnings (EBITDA): 237M vs. CAI (111M). CAI has more cash in the bank: 823M vs. HRMY (641M). HRMY has less debt than CAI: HRMY (159M) vs CAI (431M). CAI (907M) and HRMY (899M) have equivalent revenues.
CAIHRMYCAI / HRMY
Capitalization5.17B2.16B240%
EBITDA111M237M47%
Gain YTD-31.431-5.211603%
P/E RatioN/A13.48-
Revenue907M899M101%
Total Cash823M641M128%
Total Debt431M159M271%
FUNDAMENTALS RATINGS
CAI vs HRMY: Fundamental Ratings
CAI
HRMY
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
1
Undervalued
67
Overvalued
PROFIT vs RISK RATING
1..100
10095
SMR RATING
1..100
10049
PRICE GROWTH RATING
1..100
6044
P/E GROWTH RATING
1..100
9941
SEASONALITY SCORE
1..100
5517

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CAI's Valuation (1) in the Finance Or Rental Or Leasing industry is significantly better than the same rating for HRMY (67) in the null industry. This means that CAI’s stock grew significantly faster than HRMY’s over the last 12 months.

HRMY's Profit vs Risk Rating (95) in the null industry is in the same range as CAI (100) in the Finance Or Rental Or Leasing industry. This means that HRMY’s stock grew similarly to CAI’s over the last 12 months.

HRMY's SMR Rating (49) in the null industry is somewhat better than the same rating for CAI (100) in the Finance Or Rental Or Leasing industry. This means that HRMY’s stock grew somewhat faster than CAI’s over the last 12 months.

HRMY's Price Growth Rating (44) in the null industry is in the same range as CAI (60) in the Finance Or Rental Or Leasing industry. This means that HRMY’s stock grew similarly to CAI’s over the last 12 months.

HRMY's P/E Growth Rating (41) in the null industry is somewhat better than the same rating for CAI (99) in the Finance Or Rental Or Leasing industry. This means that HRMY’s stock grew somewhat faster than CAI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CAIHRMY
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
76%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
65%
Bearish Trend 3 days ago
78%
Momentum
ODDS (%)
Bullish Trend 5 days ago
50%
Bullish Trend 3 days ago
73%
MACD
ODDS (%)
Bullish Trend 5 days ago
20%
Bullish Trend 3 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
62%
Bullish Trend 3 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
6%
Bullish Trend 3 days ago
73%
Advances
ODDS (%)
Bullish Trend 10 days ago
53%
Bullish Trend 11 days ago
74%
Declines
ODDS (%)
Bearish Trend 18 days ago
65%
Bearish Trend 17 days ago
73%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
29%
Bearish Trend 3 days ago
84%
Aroon
ODDS (%)
Bullish Trend 3 days ago
15%
Bullish Trend 3 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
CAI
Daily Signal:
Gain/Loss:
HRMY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FLYT10.200.37
+3.76%
Tradr 2X Long FLY Daily ETF
RWX27.310.41
+1.54%
State Street® SPDR® Dow Jones® IntlREETF
ZTRE50.60N/A
N/A
F/M 3-Yr Invmt Grd Corp Bd ETF
ASHR35.16-1.18
-3.25%
Xtrackers Harvest CSI 300 China A ETF
AMDW100.45-5.43
-5.13%
Roundhill AMD WeeklyPay ETF